Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation (NCT06106308)

🧪 Interventions in This Study

• Onvansertib (DRUG)
• FOLFIRI (DRUG)
• Bevacizumab (DRUG)
• FOLFOX (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (41 Sites)

Showing the first 25 of 41 sites.

• Mayo Clinic - Arizona — Phoenix, Arizona
• The University of Arizona Cancer Center — Tucson, Arizona
• St. Bernards Medical Center — Jonesboro, Arkansas
• Highlands Oncology Group — Springdale, Arkansas
• Pacific Cancer Medical Center — Anaheim, California
• Comprehensive Blood and Cancer Center - Bakersfield — Bakersfield, California
• Orange Coast Memorial Medical Center — Fountain Valley, California
• UC San Diego Moores Cancer Center — La Jolla, California
• Norris Comprehensive Cancer Center — Los Angeles, California
• UCLA Department of Medicine-Hematology/Oncology — Los Angeles, California
• Sharp Memorial Hospital — San Diego, California
• Torrance Memorial Physician Network - Cancer Care and Infusion Center — Torrance, California
• PIH Health — Whittier, California
• Memorial Cancer Institute — Hollywood, Florida
• Mayo Clinic - Florida — Jacksonville, Florida
• Cleveland Clinic Martin Health — Stuart, Florida
• Kaiser Permanente — Honolulu, Hawaii
• Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
• The University of Kansas Cancer Center - Westwood — Westwood, Kansas
• Cancer Center of Kansas — Wichita, Kansas
• Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion — Grand Rapids, Michigan
• Mayo Clinic Cancer Center — Rochester, Minnesota
• Saint Luke's Hospital — Kansas City, Missouri
• Washington University School of Medicine Center for Advanced Medicine — St Louis, Missouri
• CCCN — Las Vegas, Nevada

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Colorectal Cancer

• A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer — Phoenix, Arizona
• Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer — Toronto, Ontario
• A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) — Los Angeles, California
• A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer — Duarte, California
• A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer — Los Angeles, California

Explore by condition: All Metastatic Colorectal Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.